Literature DB >> 29858439

Lesson of the month 1: To stop a fit, but swinging low.

Osakpolor Ogbebor1, Ankit Agrawal2, Balaji Yegneswaran2.   

Abstract

This is a case of an elderly woman who presented to our emergency room with an episode of a witnessed fall. The past medical history of the patient was significant for post-stroke epilepsy for which she was on oxcarbazepine. Initial blood work showed a white cell count of 4.5, haemoglobin of 12.4, and platelet count of 15,000. Peripheral blood smear showed normal platelet and red cell morphology without clumping. The patient's history suggested that she was recently started on oxcarbazepine prompting discontinuing of the drug. The platelet count improved from 15,000 cells/mL to 80,000 cells/mL on discharge.Antiepileptic medications have been reported to cause various blood dyscrasias in the literature. There are few studies that report the association of carbamazepine and thrombocytopenia and much fewer written about oxcarbazepine. Thrombocytopenia appears to be an uncommon reported side effect of oxcarbazepine; more commonly reported side effects include dizziness, tiredness, memory problems and headache. The treatment of antiepileptic drug-associated thrombocytopenia is discontinuing the medication and monitoring the platelet counts. In few cases, immunoglobulin infusion is required. Antiepileptic drug-associated thrombocytopenia is difficult to predict and so it is imperative to monitor the platelet level when antiepileptic drugs are started and even after the medication is switched to a different one. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  Oxcarbazepine; antiepileptic drugs; carbamazepine; side effect; thrombocytopenia

Mesh:

Substances:

Year:  2018        PMID: 29858439      PMCID: PMC6334069          DOI: 10.7861/clinmedicine.18-3-256

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  7 in total

1.  Possible acute thrombocytopenia post esomeprazole and hydantoin coadministration.

Authors:  Amanda M Ranzino; Kelli R Sorrells; Shawn M Manor
Journal:  J Pharm Pract       Date:  2009-09-18

Review 2.  Carbamazepine-induced thrombocytopenia defined by a challenge test.

Authors:  T Ishikita; A Ishiguro; K Fujisawa; I Tsukimoto; T Shimbo
Journal:  Am J Hematol       Date:  1999-09       Impact factor: 10.047

Review 3.  What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?

Authors:  Dieter Schmidt; Christian E Elger
Journal:  Epilepsy Behav       Date:  2004-10       Impact factor: 2.937

4.  Oxcarbazepine-induced hemolytic anemia in a geriatric patient.

Authors:  Muhammad M Chaudhry; Maqsood Abrar; Khan Mutahir; Concha Mendoza
Journal:  Am J Ther       Date:  2008 Mar-Apr       Impact factor: 2.688

5.  Antiepileptics and blood dyscrasias: a cohort study.

Authors:  S C Blackburn; A D Oliart; L A García Rodríguez; S Pérez Gutthann
Journal:  Pharmacotherapy       Date:  1998 Nov-Dec       Impact factor: 4.705

6.  Uncontrolled headache induced by oxcarbazepine.

Authors:  Elcio Juliato Piovesan; Helio Ghizoni Teive; Luciano de Paola; Carlos Eduardo Silvado; Ana Crippa; Vanise Campos Gomes Amaral; Marcos Vinicius Della Colleta; Fabrizio Di Stani; Lineu Cesar Werneck
Journal:  J Headache Pain       Date:  2007-10-23       Impact factor: 7.277

7.  Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP).

Authors:  E Besi; D R Boniface; R Cregg; J M Zakrzewska
Journal:  J Headache Pain       Date:  2015-09-03       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.